LISA KELLER: Open Payments
NPI 1205051562 · LITTLETON, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,152 in 58 payments from 20 companies in 2025. Trend: 2023 $1,590 · 2024 $1,861 · 2025 $1,152
Food & beverage: $1,152
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 10 | $262 |
| PFIZER INC. | 10 | $139 |
| Otsuka America Pharmaceutical, Inc. | 9 | $138 |
| AstraZeneca Pharmaceuticals LP | 5 | $84 |
| Novo Nordisk Inc | 3 | $81 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $66 |
| Sumitomo Pharma America, Inc. | 2 | $52 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $36 |
| Merck Sharp & Dohme LLC | 2 | $32 |
| Lilly USA, LLC | 2 | $31 |
Products named: REXULTI, VRAYLAR, Wegovy, ZAVZPRET, CAPLYTA, UBRELVY, PREVNAR 20, QULIPTA.
Industry payments across CO — which companies pay providers there.
